Evaluating the potential of the GFAP‐KLH immune‐tolerizing vaccine for type 1 diabetes in mice. Issue 1 (20th December 2016)

• Record Type: Journal Article
• Authors: Pang, Zhengda; Higuchi, Masayoshi; Koriyama, Hiroshi; Yoshida, Shota; Kurinami, Hitomi; Shimamura, Munehisa; Takami, Yoichi; Rakugi, Hiromi; Morishita, Ryuichi; Nakagami, Hironori
• Is Part Of: FEBS letters. Volume 591:Issue 1(2017)
• Page Start: 129
• Page End: 136
• Publication Date: 2016-12-20
• Subjects: glial fibrillary acidic protein -- type 1 diabetes -- vaccine; Biochemistry -- Periodicals; Biophysics -- Periodicals; Molecular biology -- Periodicals; Biochimie -- Périodiques; Biochemistry; Biophysics; Molecular biology; Periodicals; 572.05
• DOI: 10.1002/1873-3468.12511
• Languages: English
• ISSNs: 0014-5793

Abstract

Abstract : Glial fibrillary acidic protein (GFAP), expressed in peri‐islet Schwann cells, is a novel target for the treatment of type 1 diabetes mellitus (T1DM). We designed a GFAP immune‐tolerizing vaccine that successfully suppresses hyperglycemia and enhances C peptide secretion. The GFAP vaccine significantly prevented T cell infiltration into pancreatic islets. Moreover, after GFAP vaccination, naïve T‐cell differentiation shifted from a cytotoxic Th1‐ to a Th2‐biased humoral response. These results indicate that as a novel target, GFAP reliably predicts the development of T1DM, and that the GFAP vaccine successfully delays the progression of T1DM by regulating T‐cell differentiation. Abstract :